Attitudes of healthcare professionals and drug regulators about progression-free survival as endpoint in the advanced cancer setting
To describe the attitudes of healthcare professionals and drug regulators about progression-free survival (PFS) as efficacy endpoint in clinical trials with patients with advanced cancer and to explore to what extent these attitudes influence the willingness to trade between PFS and toxicity.
Source: European Journal of Cancer - Category: Cancer & Oncology Authors: Douwe Postmus, Saskia Litiere, Jan Bogaerts, Jurjen Versluis, Jan Cornelissen, Francesco Pignatti Tags: Original Research Source Type: research